On our updated estimates, the Swedencare share is trading at a ‘22e-‘23e EV/EBIT of 52x-42x. This corresponds to the share trading ~20% above the recently IPO’d Vimian, which has underperformed Swedencare during the last three months by almost 30pp.
Q3 report due on 28 October
We expect sales & adj. EBIT of SEK 236m & SEK 56m
FY’21e EBIT down 5%, LT estimates more or less intact
LÄS MER